Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to determine if enhanced daily application of disinfectant with persistent 24-hour activity decreases the environmental bioburden compared to standard practice.
Full description
The study investigator will evaluate the effectiveness of daily disinfection strategies on environmental contamination in acute care hospital rooms.
The trial will be conducted in acute care hospital rooms at Duke University Hospital, Duke Regional Hospital, Duke Raleigh Hospital, and the University of North Carolina Medical Center. In each study room, one half will be randomized to the control arm, and the other half will be randomized to one of the two intervention arms. Two separate randomization steps will occur. First, each room will be randomized to Intervention 1 or Intervention 2. Second, the half of the room to which the intervention will be applied (e.g., right vs. left) will be randomly selected. The control arm will receive no interventions. Rooms randomized to the control arm will undergo routine disinfection via existing Environmental Services (EVS) protocols. All study hospitals routinely use EPA-registered disinfectants for low-level disinfection of hospital room surfaces. Intervention 1 is the standard EPA-registered disinfectant to each study surface and will be applied by the study team. Intervention 2 is a quaternary ammonium, salt-based, 24-hour continuously active germicidal wipe (Sani-24®) to each study surface and will be applied by the study team.
Three different methods will be used for disinfection. No changes to baseline and routine disinfection practices will occur during the study. EVS employees at study hospitals will be responsible for the total room cleaning and disinfection throughout the study. Tasks will be separated between study team members to maintain blinding.Room contamination will be measured before the application of the interventions on study day 1 and every 24 hours for 3 subsequent days, for a total of 4 days. Secondary outcomes include evaluation for epidemiologically important pathogens (EIP), including me staphylococcus aureus (MRSA or MSSA), extended spectrum beta-lactamase (ESBL) or carbapenem-resistant Enterobacteriaceae (CRE) producing Enterobacterales, vancomycin-resistant Enterococci (VRE), vancomycin-susceptible Enterococci (VSE), Acinetobacter spp., and Pseudomonas aeruginosa.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Adult patient admitted to the room
- Patient spent ≥1 night in room prior to enrollment
- Anticipated patient stay of ≥48 hours
- On contact precautions (for any reason) and/or has positive culture for EIP at the time of room admission
Exclusion criteria
- Patient stay is expect to be <48 hours
- Patient age <18, even if on adult ward
- Patient admitted on respiratory precautions due to coronavirus disease (COVID-19), influenza, or respiratory syncytial virus (RSV)
- Patient on contact precautions due to C. difficile
Trial design
Primary purpose
Allocation
Interventional model
Masking
918 participants in 3 patient groups
Trial contacts and locations
Loading...
Central trial contact
Amanda M Graves, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal